Hiroshi Ureshino

Title: Hiroshi Ureshino: Innovator in Therapeutic Agents

Introduction

Hiroshi Ureshino is a notable inventor based in Saga, Japan. He has made significant contributions to the field of therapeutic agents, particularly in addressing challenges related to TKI-resistant chronic myeloid leukemia (CML). His innovative approach focuses on developing compounds that can serve as effective alternatives to existing treatments.

Latest Patents

Ureshino holds a patent for the use of a DNMT inhibitor. This patent aims to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML, intended to replace the injection “Dacogen®,” which has been clinically used for high-risk myelodysplastic syndrome and acute myeloid leukemia. The compound demonstrates remarkable stability against cytidine deaminase, a hydrolytic enzyme, and is effectively absorbed in vivo through oral administration. It is incorporated into the biosynthesis route of nucleic acid and exhibits the ability to inhibit DNA methyltransferase (DNMT).

Career Highlights

Throughout his career, Ureshino has worked with reputable organizations, including Ohara Pharmaceutical Co., Ltd. and Saga University. His experience in these institutions has allowed him to refine his research and contribute to advancements in medical therapies.

Collaborations

Ureshino has collaborated with various professionals in his field, including Yuki Kurahashi. These partnerships have facilitated the exchange of ideas and fostered innovation in therapeutic development.

Conclusion

Hiroshi Ureshino's work in developing therapeutic agents for TKI-resistant CML showcases his commitment to advancing medical science. His innovative solutions have the potential to significantly impact the treatment landscape for patients facing these challenging conditions.